Andrić Zoran, Randjelović Tomislav, Kovčin Vladimir, Gutović Jasmina, Crevar Slobodanka, Murtezani Zafir, Kostić Sanja
Srp Arh Celok Lek. 2012 May-Jun;140(5-6):305-12. doi: 10.2298/sarh1206305a.
Still there is no consensus on the choice of the most efficient and the least toxic chemotherapy regimen in the treatment of advanced gastric cancer. Nowadays few therapy protocols are available for treating this disease.
Study was conducted to compare the efficacy and toxicity of FAM (flurouracil, doxorubicin, mitomycin C) with CDDP and FU/FA (cisplatin, 5-fluorouracil, leucovorin) protocols in patients with locally advanced and metastatic gastric cancer.
This randomized study involved a group of 50 patients with locally advanced or metastatic gastric cancer, who had not previously undergone chemotherapy treatment. Progression free survival, overall survival and drug toxicity were evaluated. For statistical analysis chi-squaretest, Kaplan-Meier curve and the log rank test were used.
The overall response rate was 20% in the group treated with FAM and 24% in the group treated with CDDP, FU/FA (4% of patients from each group had complete response), but without significant statistical difference. Median survival was 10.9 months in the FAM group and 11.8 months in CDDP, FU/FA group, with no statistically significant difference. Non-haematological and haematological toxicities of CDDP, FU/FA were considerably less frequent than of FAM, and there was no treatment related deaths in any of the groups.
Both investigated regimens demonstrated moderate efficacy. The study shows in favour of justified application of both protocols, while in regard to toxicity CDDP and FU/FA can be recommended as preferable treatment for locally advanced and metastatic gastric cancer. New strategies should be considered for better efficacy in the treatment of advanced gastric cancer. New strategies are necessary with the goal to achieve a better therapeutic effect.
在晚期胃癌治疗中,对于选择最有效且毒性最小的化疗方案仍未达成共识。如今,可用于治疗该疾病的治疗方案很少。
进行本研究以比较FAM(氟尿嘧啶、阿霉素、丝裂霉素C)与顺铂联合FU/FA(顺铂、5-氟尿嘧啶、亚叶酸钙)方案治疗局部晚期和转移性胃癌患者的疗效和毒性。
这项随机研究纳入了一组50例局部晚期或转移性胃癌患者,这些患者此前未接受过化疗治疗。评估无进展生存期、总生存期和药物毒性。采用卡方检验、Kaplan-Meier曲线和对数秩检验进行统计分析。
FAM治疗组的总缓解率为20%,顺铂联合FU/FA治疗组为24%(每组各有4%的患者完全缓解),但无显著统计学差异。FAM组的中位生存期为10.9个月,顺铂联合FU/FA组为11.8个月,无统计学显著差异。顺铂联合FU/FA的非血液学和血液学毒性比FAM的发生率低得多,且两组均无治疗相关死亡。
两种研究方案均显示出中等疗效。该研究表明两种方案的应用都是合理的,而就毒性而言,顺铂联合FU/FA可推荐为局部晚期和转移性胃癌的更优治疗方案。应考虑新的策略以提高晚期胃癌的治疗效果。为实现更好的治疗效果,新策略是必要的。